| 【行业研究】中国医药 - 2024年度业绩回顾：创新药独占鳌头 |
| 【Sector Research】Auto - 1Q25 sales volume, discounts may lead to larger earnings divergence |
| 【Sector Research】Technology - Implications of US reciprocal tariffs on supply chain |
| 【Company Research】XtalPi (2228 HK) - AI-driven innovation unlocks expansive commercial prospects |
| 【Company Research】Binjiang Service (3316 HK) - Expansion outside Zhejiang to support GFA growth; Maintain BUY |
| 【Company Research】Yonyou (600588 CH) - Striving for large-scale loss reduction in 2025 |
| 【Company Research】New Hope Services (3658 HK) - Third party expansion advances to higher-end level, maintain BUY |
| 【Company Research】SANY International (631 HK) - Set for a recovery |
| 【公司研究】固生堂 (2273 HK) - AI赋能中医服务龙头 |
| 【Company Research】Akeso (9926 HK) - AK112 to validate its potential as next-generation IO therapy |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
